175 related articles for article (PubMed ID: 24878433)
1. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.
Qi WX; Shen Z; Tang LN; Yao Y
Crit Rev Oncol Hematol; 2014 Nov; 92(2):71-82. PubMed ID: 24878433
[TBL] [Abstract][Full Text] [Related]
2. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis.
Liu B; Ding F; Zhang D; Wei GH
Cancer Chemother Pharmacol; 2017 Sep; 80(3):487-495. PubMed ID: 28695268
[TBL] [Abstract][Full Text] [Related]
3. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
5. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.
Qi WX; Tang LN; Sun YJ; He AN; Lin F; Shen Z; Yao Y
Ann Oncol; 2013 Dec; 24(12):2943-52. PubMed ID: 23921791
[TBL] [Abstract][Full Text] [Related]
8. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.
Qi WX; Shen Z; Tang LN; Yao Y
Br J Clin Pharmacol; 2014 Oct; 78(4):748-62. PubMed ID: 24661224
[TBL] [Abstract][Full Text] [Related]
9. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
Sivendran S; Liu Z; Portas LJ; Yu M; Hahn N; Sonpavde G; Oh WK; Galsky MD
Cancer Treat Rev; 2012 Nov; 38(7):919-25. PubMed ID: 22651902
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
Li J; Gu J
Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
[TBL] [Abstract][Full Text] [Related]
11. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
Ding F; Liu B; Wang Y
J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
Qi WX; Min DL; Shen Z; Sun YJ; Lin F; Tang LN; He AN; Yao Y
Int J Cancer; 2013 Jun; 132(12):2967-74. PubMed ID: 23225494
[TBL] [Abstract][Full Text] [Related]
13. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis.
Zhang ZF; Wang T; Liu LH; Guo HQ
PLoS One; 2014; 9(3):e90135. PubMed ID: 24621598
[TBL] [Abstract][Full Text] [Related]
14. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
Petrelli F; Cabiddu M; Borgonovo K; Barni S
Ann Oncol; 2012 Jul; 23(7):1672-9. PubMed ID: 22241897
[TBL] [Abstract][Full Text] [Related]
15. Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review.
Bai Y; Li JY; Li J; Zhang B; Liu YH; Zhang BY; Jing J
Oncotarget; 2019 Jun; 10(41):4205-4212. PubMed ID: 31289618
[No Abstract] [Full Text] [Related]
16. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Li J; Gu J
Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
Zhang W; Feng LJ; Teng F; Li YH; Zhang X; Ran YG
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):311-320. PubMed ID: 32105149
[No Abstract] [Full Text] [Related]
18. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.
Ghatalia P; Je Y; Mouallem NE; Nguyen PL; Trinh QD; Sonpavde G; Choueiri TK
Crit Rev Oncol Hematol; 2015 Mar; 93(3):257-76. PubMed ID: 25523486
[TBL] [Abstract][Full Text] [Related]
19. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.
Li J; Gu J
Eur J Clin Pharmacol; 2017 Oct; 73(10):1209-1217. PubMed ID: 28710508
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
